A neutralizing-protective supersite of human monoclonal antibodies for yellow fever virus
The yellow fever virus (YFV) is a life-threatening human pathogen. Owing to the lack of available therapeutics, non-vaccinated individuals are at risk. Here, we isolated eight human monoclonal antibodies that neutralize YFV infection. Five recognized overlapping epitopes and exhibited potent neutral...
Saved in:
| Published in | Innovation (New York, NY) Vol. 3; no. 6; p. 100323 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Elsevier Inc
08.11.2022
Elsevier |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The yellow fever virus (YFV) is a life-threatening human pathogen. Owing to the lack of available therapeutics, non-vaccinated individuals are at risk. Here, we isolated eight human monoclonal antibodies that neutralize YFV infection. Five recognized overlapping epitopes and exhibited potent neutralizing activity. Two (YD6 and YD73) were ultra-potent and conferred complete protection against the lethal challenge of YFV as both prophylactics and therapeutics in a mouse model. Crystal structures revealed that YD6 engaged the YFV envelope protein in both pre- and post-fusion states, suggesting viral inhibition by a “double-lock” mechanism. The recognition determinants for YD6 and YD73 are clustered at the premembrane (prM)-binding site. Notably, antibodies targeting this site were present in minute traces in YFV-infected individuals but contributed significantly to neutralization, suggesting a vulnerable supersite of YFV. We provide two promising candidates for immunotherapy against YFV, and the supersite represents an ideal target for epitope-based vaccine design.
[Display omitted]
•Two monoclonal antibodies (mAbs, YD6 and YD73) have prophylaxis and therapy efficacy against the lethal challenge of YFV•The crystal structures of mAbs bound to YFV envelope protein in pre-fusion and post-fusion conformations•Two mAbs (YD6 and YD73) inhibit YFV infection at multiple steps•The premembrane-binding region is a supersite recognized by YFV neutralizing mAbs |
|---|---|
| AbstractList | The yellow fever virus (YFV) is a life-threatening human pathogen. Owing to the lack of available therapeutics, non-vaccinated individuals are at risk. Here, we isolated eight human monoclonal antibodies that neutralize YFV infection. Five recognized overlapping epitopes and exhibited potent neutralizing activity. Two (YD6 and YD73) were ultra-potent and conferred complete protection against the lethal challenge of YFV as both prophylactics and therapeutics in a mouse model. Crystal structures revealed that YD6 engaged the YFV envelope protein in both pre- and post-fusion states, suggesting viral inhibition by a “double-lock” mechanism. The recognition determinants for YD6 and YD73 are clustered at the premembrane (prM)-binding site. Notably, antibodies targeting this site were present in minute traces in YFV-infected individuals but contributed significantly to neutralization, suggesting a vulnerable supersite of YFV. We provide two promising candidates for immunotherapy against YFV, and the supersite represents an ideal target for epitope-based vaccine design.
[Display omitted]
•Two monoclonal antibodies (mAbs, YD6 and YD73) have prophylaxis and therapy efficacy against the lethal challenge of YFV•The crystal structures of mAbs bound to YFV envelope protein in pre-fusion and post-fusion conformations•Two mAbs (YD6 and YD73) inhibit YFV infection at multiple steps•The premembrane-binding region is a supersite recognized by YFV neutralizing mAbs The yellow fever virus (YFV) is a life-threatening human pathogen. Owing to the lack of available therapeutics, non-vaccinated individuals are at risk. Here, we isolated eight human monoclonal antibodies that neutralize YFV infection. Five recognized overlapping epitopes and exhibited potent neutralizing activity. Two (YD6 and YD73) were ultra-potent and conferred complete protection against the lethal challenge of YFV as both prophylactics and therapeutics in a mouse model. Crystal structures revealed that YD6 engaged the YFV envelope protein in both pre- and post-fusion states, suggesting viral inhibition by a “double-lock” mechanism. The recognition determinants for YD6 and YD73 are clustered at the premembrane (prM)-binding site. Notably, antibodies targeting this site were present in minute traces in YFV-infected individuals but contributed significantly to neutralization, suggesting a vulnerable supersite of YFV. We provide two promising candidates for immunotherapy against YFV, and the supersite represents an ideal target for epitope-based vaccine design. The yellow fever virus (YFV) is a life-threatening human pathogen. Owing to the lack of available therapeutics, non-vaccinated individuals are at risk. Here, we isolated eight human monoclonal antibodies that neutralize YFV infection. Five recognized overlapping epitopes and exhibited potent neutralizing activity. Two (YD6 and YD73) were ultra-potent and conferred complete protection against the lethal challenge of YFV as both prophylactics and therapeutics in a mouse model. Crystal structures revealed that YD6 engaged the YFV envelope protein in both pre- and post-fusion states, suggesting viral inhibition by a "double-lock" mechanism. The recognition determinants for YD6 and YD73 are clustered at the premembrane (prM)-binding site. Notably, antibodies targeting this site were present in minute traces in YFV-infected individuals but contributed significantly to neutralization, suggesting a vulnerable supersite of YFV. We provide two promising candidates for immunotherapy against YFV, and the supersite represents an ideal target for epitope-based vaccine design.The yellow fever virus (YFV) is a life-threatening human pathogen. Owing to the lack of available therapeutics, non-vaccinated individuals are at risk. Here, we isolated eight human monoclonal antibodies that neutralize YFV infection. Five recognized overlapping epitopes and exhibited potent neutralizing activity. Two (YD6 and YD73) were ultra-potent and conferred complete protection against the lethal challenge of YFV as both prophylactics and therapeutics in a mouse model. Crystal structures revealed that YD6 engaged the YFV envelope protein in both pre- and post-fusion states, suggesting viral inhibition by a "double-lock" mechanism. The recognition determinants for YD6 and YD73 are clustered at the premembrane (prM)-binding site. Notably, antibodies targeting this site were present in minute traces in YFV-infected individuals but contributed significantly to neutralization, suggesting a vulnerable supersite of YFV. We provide two promising candidates for immunotherapy against YFV, and the supersite represents an ideal target for epitope-based vaccine design. The yellow fever virus (YFV) is a life-threatening human pathogen. Owing to the lack of available therapeutics, non-vaccinated individuals are at risk. Here, we isolated eight human monoclonal antibodies that neutralize YFV infection. Five recognized overlapping epitopes and exhibited potent neutralizing activity. Two (YD6 and YD73) were ultra-potent and conferred complete protection against the lethal challenge of YFV as both prophylactics and therapeutics in a mouse model. Crystal structures revealed that YD6 engaged the YFV envelope protein in both pre- and post-fusion states, suggesting viral inhibition by a “double-lock” mechanism. The recognition determinants for YD6 and YD73 are clustered at the premembrane (prM)-binding site. Notably, antibodies targeting this site were present in minute traces in YFV-infected individuals but contributed significantly to neutralization, suggesting a vulnerable supersite of YFV. We provide two promising candidates for immunotherapy against YFV, and the supersite represents an ideal target for epitope-based vaccine design. • Two monoclonal antibodies (mAbs, YD6 and YD73) have prophylaxis and therapy efficacy against the lethal challenge of YFV • The crystal structures of mAbs bound to YFV envelope protein in pre-fusion and post-fusion conformations • Two mAbs (YD6 and YD73) inhibit YFV infection at multiple steps • The premembrane-binding region is a supersite recognized by YFV neutralizing mAbs |
| ArticleNumber | 100323 |
| Author | Dai, Lianpan Song, Rui Wang, Qihui Chai, Yan Qi, Jianxun Liu, Wenjun Gao, George F. Chen, Zhihai Li, Shihua Li, Yan Wu, Lili Tong, Zhou Duan, Xiaomin Liang, Mifang Yan, Jinghua Ma, Sufang Ren, Shuning |
| Author_xml | – sequence: 1 givenname: Yan surname: Li fullname: Li, Yan organization: CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China – sequence: 2 givenname: Zhihai surname: Chen fullname: Chen, Zhihai organization: Center of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China – sequence: 3 givenname: Lili surname: Wu fullname: Wu, Lili organization: CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China – sequence: 4 givenname: Lianpan surname: Dai fullname: Dai, Lianpan organization: CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China – sequence: 5 givenname: Jianxun surname: Qi fullname: Qi, Jianxun organization: CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China – sequence: 6 givenname: Yan surname: Chai fullname: Chai, Yan organization: CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China – sequence: 7 givenname: Shihua surname: Li fullname: Li, Shihua organization: CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China – sequence: 8 givenname: Qihui surname: Wang fullname: Wang, Qihui organization: CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China – sequence: 9 givenname: Zhou surname: Tong fullname: Tong, Zhou organization: CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China – sequence: 10 givenname: Sufang surname: Ma fullname: Ma, Sufang organization: CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China – sequence: 11 givenname: Xiaomin surname: Duan fullname: Duan, Xiaomin organization: CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China – sequence: 12 givenname: Shuning surname: Ren fullname: Ren, Shuning organization: College of Veterinary Medicine, China Agricultural University, Beijing 100193, China – sequence: 13 givenname: Rui surname: Song fullname: Song, Rui organization: Center of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China – sequence: 14 givenname: Mifang surname: Liang fullname: Liang, Mifang organization: National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing 102206, China – sequence: 15 givenname: Wenjun surname: Liu fullname: Liu, Wenjun organization: CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China – sequence: 16 givenname: Jinghua surname: Yan fullname: Yan, Jinghua email: yanjh@im.ac.cn organization: CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China – sequence: 17 givenname: George F. surname: Gao fullname: Gao, George F. email: gaof@im.ac.cn organization: CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China |
| BookMark | eNp9kc1u1TAQRiNUJErpC7Dykk1u_RcnkRBSVQGtVIkNLFhZtjO5navEvthJaHl6HFIhyqIr2-P5jq05r4sTHzwUxVtGd4wydXHY3aP3O045zwUquHhRnHKlVKnqqjn5Z_-qOE_pQCnlFeOSqdPi-yXxME_RDPgL_b48xjCBm3ABkuYjxIQTkNCTu3k0nozBBzcEbwZi_IQ2dAiJ9CGSBxiG8JP0sEAkC8Y5vSle9mZIcP64nhXfPn38enVd3n75fHN1eVs6yYQomxokk7ISrHGsVYa1PWOOic46KbilPatcw4x0lipJhRFWOOqUtVVrQColzoqbjdsFc9DHiKOJDzoY1H8KIe61iRO6AbS1lpnaMKpEBlZ1PtmG8ta6ThinaGZ92FjH2Y7QOfDrZJ5An954vNP7sOi24m0l6gx49wiI4ccMadIjJpdnYzyEOWlecy5YxWSbW_nW6mJIKUL_9xlG9epVH_TqVa9e9eY1h5r_Qg4nM2FYv4PD89H3WxSyjAUh6uQQvIMOYzaep4XPxX8DoVrCVQ |
| CitedBy_id | crossref_primary_10_1126_scitranslmed_ade5795 |
| Cites_doi | 10.1038/sj.emboj.7600064 10.1038/ncomms13679 10.1016/j.chom.2016.04.013 10.1111/j.1600-065X.2008.00676.x 10.1038/nature18938 10.1126/science.abd0831 10.1016/j.vaccine.2017.03.032 10.1016/j.cell.2017.04.024 10.1016/j.virol.2005.04.031 10.1016/S0140-6736(16)31546-X 10.1038/s41586-020-2381-y 10.1038/ni.3058 10.1038/nature02165 10.1038/s41564-019-0411-z 10.1038/nrmicro1067 10.1371/journal.pone.0016059 10.1016/j.celrep.2018.12.065 10.1016/j.antiviral.2016.01.002 10.1038/s41467-020-19625-9 10.1126/science.abc2241 10.1128/JVI.01049-17 10.15252/embr.201745302 10.1126/scitranslmed.aac4241 10.1016/j.cell.2018.02.025 10.1126/scitranslmed.aai8336 10.1016/S1473-3099(17)30494-2 10.1016/j.cell.2017.09.002 10.1038/nature14130 10.1002/iub.1556 |
| ContentType | Journal Article |
| Copyright | 2022 The Author(s) 2022 The Author(s). 2022 The Author(s) 2022 |
| Copyright_xml | – notice: 2022 The Author(s) – notice: 2022 The Author(s). – notice: 2022 The Author(s) 2022 |
| DBID | 6I. AAFTH AAYXX CITATION 7X8 5PM DOA |
| DOI | 10.1016/j.xinn.2022.100323 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| EISSN | 2666-6758 |
| ExternalDocumentID | oai_doaj_org_article_bbb1a7a1063a4c57b1ab8029bcd3ac60 PMC9529537 10_1016_j_xinn_2022_100323 S2666675822001199 |
| GroupedDBID | 6I. AAEDW AAFTH AAXUO AEXQZ ALMA_UNASSIGNED_HOLDINGS AMRAJ EBS FDB GROUPED_DOAJ M41 M~E OK1 ROL RPM 0R~ AALRI AAMRU AAYWO AAYXX ACVFH ADCNI ADVLN AEUPX AFPUW AIGII AITUG AKBMS AKYEP APXCP CITATION 7X8 5PM |
| ID | FETCH-LOGICAL-c4133-87e41445318c196a19f11c13dbc432b0f15c81a4cb06403a3b3c0c6bb59ae4663 |
| IEDL.DBID | DOA |
| ISSN | 2666-6758 |
| IngestDate | Wed Aug 27 01:31:27 EDT 2025 Thu Aug 21 18:39:58 EDT 2025 Fri Jul 11 16:28:42 EDT 2025 Thu Apr 24 23:12:05 EDT 2025 Tue Jul 01 03:48:43 EDT 2025 Fri Feb 23 02:39:31 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | neutralizing antibody yellow fever virus complex structure prM-binding site supersite human monoclonal antibody |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4133-87e41445318c196a19f11c13dbc432b0f15c81a4cb06403a3b3c0c6bb59ae4663 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally |
| OpenAccessLink | https://doaj.org/article/bbb1a7a1063a4c57b1ab8029bcd3ac60 |
| PQID | 2722315149 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_bbb1a7a1063a4c57b1ab8029bcd3ac60 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9529537 proquest_miscellaneous_2722315149 crossref_primary_10_1016_j_xinn_2022_100323 crossref_citationtrail_10_1016_j_xinn_2022_100323 elsevier_sciencedirect_doi_10_1016_j_xinn_2022_100323 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-11-08 |
| PublicationDateYYYYMMDD | 2022-11-08 |
| PublicationDate_xml | – month: 11 year: 2022 text: 2022-11-08 day: 08 |
| PublicationDecade | 2020 |
| PublicationTitle | Innovation (New York, NY) |
| PublicationYear | 2022 |
| Publisher | Elsevier Inc Elsevier |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier |
| References | Modis, Ogata, Clements, Harrison (bib16) 2004; 427 Deng, Dai, Ji (bib20) 2011; 6 Fibriansah, Lok (bib19) 2016; 128 Daffis, Kontermann, Korimbocus (bib21) 2005; 337 Gao (bib2) 2018; 172 Elachola, Ditekemena, Zhuo (bib3) 2016; 388 Lu, Xiao, Li (bib22) 2019; 26 Wang, Yan, Gao (bib17) 2017; 91 Rey, Stiasny, Vaney (bib1) 2018; 19 Dai, Song, Lu (bib13) 2016; 19 Wu, Wang, Shen (bib9) 2020; 368 Ngwuta, Chen, Modjarrad (bib25) 2015; 7 Lataillade, Vazeille, Obadia (bib6) 2020; 11 Shi, Shan, Duan (bib10) 2020; 584 Dejnirattisai, Wongwiwat, Supasa (bib12) 2015; 16 Baum, Fulton, Wloga (bib11) 2020; 369 Barrett (bib4) 2017; 35 Robbiani, Bozzacco, Keeffe (bib28) 2017; 169 Wilder-Smith (bib5) 2017; 17 Bressanelli, Stiasny, Allison (bib15) 2004; 23 Wang, Ma, Wu (bib23) 2019; 4 Wang, Bardelli, Espinosa (bib7) 2017; 171 Mukhopadhyay, Kuhn, Rossmann (bib14) 2005; 3 Zhang, Kostyuchenko, Ng (bib29) 2016; 7 Rouvinski, Guardado-Calvo, Barba-Spaeth (bib27) 2015; 520 Barba-Spaeth, Dejnirattisai, Rouvinski (bib8) 2016; 536 Wang, Yang, Liu (bib24) 2016; 8 Diamond, Pierson, Fremont (bib26) 2008; 225 Dai, Wang, Qi (bib18) 2016; 68 Wang (10.1016/j.xinn.2022.100323_bib24) 2016; 8 Baum (10.1016/j.xinn.2022.100323_bib11) 2020; 369 Dejnirattisai (10.1016/j.xinn.2022.100323_bib12) 2015; 16 Modis (10.1016/j.xinn.2022.100323_bib16) 2004; 427 Wang (10.1016/j.xinn.2022.100323_bib23) 2019; 4 Robbiani (10.1016/j.xinn.2022.100323_bib28) 2017; 169 Zhang (10.1016/j.xinn.2022.100323_bib29) 2016; 7 Wilder-Smith (10.1016/j.xinn.2022.100323_bib5) 2017; 17 Wu (10.1016/j.xinn.2022.100323_bib9) 2020; 368 Daffis (10.1016/j.xinn.2022.100323_bib21) 2005; 337 Shi (10.1016/j.xinn.2022.100323_bib10) 2020; 584 Deng (10.1016/j.xinn.2022.100323_bib20) 2011; 6 Ngwuta (10.1016/j.xinn.2022.100323_bib25) 2015; 7 Elachola (10.1016/j.xinn.2022.100323_bib3) 2016; 388 Wang (10.1016/j.xinn.2022.100323_bib17) 2017; 91 Dai (10.1016/j.xinn.2022.100323_bib18) 2016; 68 Lataillade (10.1016/j.xinn.2022.100323_bib6) 2020; 11 Barba-Spaeth (10.1016/j.xinn.2022.100323_bib8) 2016; 536 Wang (10.1016/j.xinn.2022.100323_bib7) 2017; 171 Rey (10.1016/j.xinn.2022.100323_bib1) 2018; 19 Diamond (10.1016/j.xinn.2022.100323_bib26) 2008; 225 Fibriansah (10.1016/j.xinn.2022.100323_bib19) 2016; 128 Dai (10.1016/j.xinn.2022.100323_bib13) 2016; 19 Lu (10.1016/j.xinn.2022.100323_bib22) 2019; 26 Gao (10.1016/j.xinn.2022.100323_bib2) 2018; 172 Rouvinski (10.1016/j.xinn.2022.100323_bib27) 2015; 520 Bressanelli (10.1016/j.xinn.2022.100323_bib15) 2004; 23 Barrett (10.1016/j.xinn.2022.100323_bib4) 2017; 35 Mukhopadhyay (10.1016/j.xinn.2022.100323_bib14) 2005; 3 |
| References_xml | – volume: 171 start-page: 229 year: 2017 end-page: 241.e15 ident: bib7 article-title: A human bi-specific antibody against Zika virus with high therapeutic potential publication-title: Cell – volume: 584 start-page: 120 year: 2020 end-page: 124 ident: bib10 article-title: A human neutralizing antibody targets the receptor binding site of SARS-CoV-2 publication-title: Nature – volume: 91 start-page: e01049-17 year: 2017 end-page: e01017 ident: bib17 article-title: Monoclonal antibodies against Zika virus: therapeutics and their implications for vaccine design publication-title: J. Virol. – volume: 128 start-page: 7 year: 2016 end-page: 19 ident: bib19 article-title: The development of therapeutic antibodies against dengue virus publication-title: Antivir. Res. – volume: 520 start-page: 109 year: 2015 end-page: 113 ident: bib27 article-title: Recognition determinants of broadly neutralizing human antibodies against dengue viruses publication-title: Nature – volume: 19 start-page: 696 year: 2016 end-page: 704 ident: bib13 article-title: Structures of the Zika virus envelope protein and its complex with a flavivirus broadly protective antibody publication-title: Cell Host Microbe – volume: 3 start-page: 13 year: 2005 end-page: 22 ident: bib14 article-title: A structural perspective of the flavivirus life cycle publication-title: Nat. Rev. Microbiol. – volume: 16 start-page: 170 year: 2015 end-page: 177 ident: bib12 article-title: A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus publication-title: Nat. Immunol. – volume: 19 start-page: 206 year: 2018 end-page: 224 ident: bib1 article-title: The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design publication-title: EMBO Rep. – volume: 11 start-page: 5801 year: 2020 ident: bib6 article-title: Risk of yellow fever virus transmission in the Asia-Pacific region publication-title: Nat. Commun. – volume: 26 start-page: 438 year: 2019 end-page: 446.e5 ident: bib22 article-title: Double lock of a human neutralizing and protective monoclonal antibody targeting the yellow fever virus envelope publication-title: Cell Rep. – volume: 8 start-page: 369ra179 year: 2016 ident: bib24 article-title: Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus publication-title: Sci. Transl. Med. – volume: 7 start-page: 13679 year: 2016 ident: bib29 article-title: Neutralization mechanism of a highly potent antibody against Zika virus publication-title: Nat. Commun. – volume: 4 start-page: 1231 year: 2019 end-page: 1241 ident: bib23 article-title: Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus publication-title: Nat. Microbiol. – volume: 369 start-page: 1014 year: 2020 end-page: 1018 ident: bib11 article-title: Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies publication-title: Science – volume: 388 start-page: 1155 year: 2016 ident: bib3 article-title: Yellow fever outbreaks, vaccine shortages and the Hajj and Olympics: call for global vigilance publication-title: Lancet – volume: 35 start-page: 5951 year: 2017 end-page: 5955 ident: bib4 article-title: Yellow fever live attenuated vaccine: a very successful live attenuated vaccine but still we have problems controlling the disease publication-title: Vaccine – volume: 225 start-page: 212 year: 2008 end-page: 225 ident: bib26 article-title: The structural immunology of antibody protection against West Nile virus publication-title: Immunol. Rev. – volume: 536 start-page: 48 year: 2016 end-page: 53 ident: bib8 article-title: Structural basis of potent Zika-dengue virus antibody cross-neutralization publication-title: Nature – volume: 169 start-page: 597 year: 2017 end-page: 609.e11 ident: bib28 article-title: Recurrent potent human neutralizing antibodies to Zika virus in Brazil and Mexico publication-title: Cell – volume: 17 start-page: 1109 year: 2017 end-page: 1111 ident: bib5 article-title: Yellow fever vaccination: estimating coverage publication-title: Lancet Infect. Dis. – volume: 7 start-page: 309ra162 year: 2015 ident: bib25 article-title: Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera publication-title: Sci. Transl. Med. – volume: 368 start-page: 1274 year: 2020 end-page: 1278 ident: bib9 article-title: A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 publication-title: Science – volume: 6 start-page: e16059 year: 2011 ident: bib20 article-title: A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein publication-title: PLoS One – volume: 172 start-page: 1157 year: 2018 end-page: 1159 ident: bib2 article-title: From "A"IV to "Z"IKV: attacks from emerging and re-emerging pathogens publication-title: Cell – volume: 337 start-page: 262 year: 2005 end-page: 272 ident: bib21 article-title: Antibody responses against wild-type yellow fever virus and the 17D vaccine strain: characterization with human monoclonal antibody fragments and neutralization escape variants publication-title: Virology – volume: 427 start-page: 313 year: 2004 end-page: 319 ident: bib16 article-title: Structure of the dengue virus envelope protein after membrane fusion publication-title: Nature – volume: 68 start-page: 783 year: 2016 end-page: 791 ident: bib18 article-title: Molecular basis of antibody-mediated neutralization and protection against flavivirus publication-title: IUBMB Life – volume: 23 start-page: 728 year: 2004 end-page: 738 ident: bib15 article-title: Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation publication-title: EMBO J. – volume: 23 start-page: 728 year: 2004 ident: 10.1016/j.xinn.2022.100323_bib15 article-title: Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation publication-title: EMBO J. doi: 10.1038/sj.emboj.7600064 – volume: 7 start-page: 13679 year: 2016 ident: 10.1016/j.xinn.2022.100323_bib29 article-title: Neutralization mechanism of a highly potent antibody against Zika virus publication-title: Nat. Commun. doi: 10.1038/ncomms13679 – volume: 19 start-page: 696 year: 2016 ident: 10.1016/j.xinn.2022.100323_bib13 article-title: Structures of the Zika virus envelope protein and its complex with a flavivirus broadly protective antibody publication-title: Cell Host Microbe doi: 10.1016/j.chom.2016.04.013 – volume: 225 start-page: 212 year: 2008 ident: 10.1016/j.xinn.2022.100323_bib26 article-title: The structural immunology of antibody protection against West Nile virus publication-title: Immunol. Rev. doi: 10.1111/j.1600-065X.2008.00676.x – volume: 536 start-page: 48 year: 2016 ident: 10.1016/j.xinn.2022.100323_bib8 article-title: Structural basis of potent Zika-dengue virus antibody cross-neutralization publication-title: Nature doi: 10.1038/nature18938 – volume: 369 start-page: 1014 year: 2020 ident: 10.1016/j.xinn.2022.100323_bib11 article-title: Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies publication-title: Science doi: 10.1126/science.abd0831 – volume: 35 start-page: 5951 year: 2017 ident: 10.1016/j.xinn.2022.100323_bib4 article-title: Yellow fever live attenuated vaccine: a very successful live attenuated vaccine but still we have problems controlling the disease publication-title: Vaccine doi: 10.1016/j.vaccine.2017.03.032 – volume: 169 start-page: 597 year: 2017 ident: 10.1016/j.xinn.2022.100323_bib28 article-title: Recurrent potent human neutralizing antibodies to Zika virus in Brazil and Mexico publication-title: Cell doi: 10.1016/j.cell.2017.04.024 – volume: 337 start-page: 262 year: 2005 ident: 10.1016/j.xinn.2022.100323_bib21 article-title: Antibody responses against wild-type yellow fever virus and the 17D vaccine strain: characterization with human monoclonal antibody fragments and neutralization escape variants publication-title: Virology doi: 10.1016/j.virol.2005.04.031 – volume: 388 start-page: 1155 year: 2016 ident: 10.1016/j.xinn.2022.100323_bib3 article-title: Yellow fever outbreaks, vaccine shortages and the Hajj and Olympics: call for global vigilance publication-title: Lancet doi: 10.1016/S0140-6736(16)31546-X – volume: 584 start-page: 120 year: 2020 ident: 10.1016/j.xinn.2022.100323_bib10 article-title: A human neutralizing antibody targets the receptor binding site of SARS-CoV-2 publication-title: Nature doi: 10.1038/s41586-020-2381-y – volume: 16 start-page: 170 year: 2015 ident: 10.1016/j.xinn.2022.100323_bib12 article-title: A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus publication-title: Nat. Immunol. doi: 10.1038/ni.3058 – volume: 427 start-page: 313 year: 2004 ident: 10.1016/j.xinn.2022.100323_bib16 article-title: Structure of the dengue virus envelope protein after membrane fusion publication-title: Nature doi: 10.1038/nature02165 – volume: 4 start-page: 1231 year: 2019 ident: 10.1016/j.xinn.2022.100323_bib23 article-title: Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus publication-title: Nat. Microbiol. doi: 10.1038/s41564-019-0411-z – volume: 3 start-page: 13 year: 2005 ident: 10.1016/j.xinn.2022.100323_bib14 article-title: A structural perspective of the flavivirus life cycle publication-title: Nat. Rev. Microbiol. doi: 10.1038/nrmicro1067 – volume: 6 start-page: e16059 year: 2011 ident: 10.1016/j.xinn.2022.100323_bib20 article-title: A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein publication-title: PLoS One doi: 10.1371/journal.pone.0016059 – volume: 26 start-page: 438 year: 2019 ident: 10.1016/j.xinn.2022.100323_bib22 article-title: Double lock of a human neutralizing and protective monoclonal antibody targeting the yellow fever virus envelope publication-title: Cell Rep. doi: 10.1016/j.celrep.2018.12.065 – volume: 128 start-page: 7 year: 2016 ident: 10.1016/j.xinn.2022.100323_bib19 article-title: The development of therapeutic antibodies against dengue virus publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2016.01.002 – volume: 11 start-page: 5801 year: 2020 ident: 10.1016/j.xinn.2022.100323_bib6 article-title: Risk of yellow fever virus transmission in the Asia-Pacific region publication-title: Nat. Commun. doi: 10.1038/s41467-020-19625-9 – volume: 368 start-page: 1274 year: 2020 ident: 10.1016/j.xinn.2022.100323_bib9 article-title: A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 publication-title: Science doi: 10.1126/science.abc2241 – volume: 91 start-page: e01049-17 year: 2017 ident: 10.1016/j.xinn.2022.100323_bib17 article-title: Monoclonal antibodies against Zika virus: therapeutics and their implications for vaccine design publication-title: J. Virol. doi: 10.1128/JVI.01049-17 – volume: 19 start-page: 206 year: 2018 ident: 10.1016/j.xinn.2022.100323_bib1 article-title: The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design publication-title: EMBO Rep. doi: 10.15252/embr.201745302 – volume: 7 start-page: 309ra162 year: 2015 ident: 10.1016/j.xinn.2022.100323_bib25 article-title: Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aac4241 – volume: 172 start-page: 1157 year: 2018 ident: 10.1016/j.xinn.2022.100323_bib2 article-title: From "A"IV to "Z"IKV: attacks from emerging and re-emerging pathogens publication-title: Cell doi: 10.1016/j.cell.2018.02.025 – volume: 8 start-page: 369ra179 year: 2016 ident: 10.1016/j.xinn.2022.100323_bib24 article-title: Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aai8336 – volume: 17 start-page: 1109 year: 2017 ident: 10.1016/j.xinn.2022.100323_bib5 article-title: Yellow fever vaccination: estimating coverage publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(17)30494-2 – volume: 171 start-page: 229 year: 2017 ident: 10.1016/j.xinn.2022.100323_bib7 article-title: A human bi-specific antibody against Zika virus with high therapeutic potential publication-title: Cell doi: 10.1016/j.cell.2017.09.002 – volume: 520 start-page: 109 year: 2015 ident: 10.1016/j.xinn.2022.100323_bib27 article-title: Recognition determinants of broadly neutralizing human antibodies against dengue viruses publication-title: Nature doi: 10.1038/nature14130 – volume: 68 start-page: 783 year: 2016 ident: 10.1016/j.xinn.2022.100323_bib18 article-title: Molecular basis of antibody-mediated neutralization and protection against flavivirus publication-title: IUBMB Life doi: 10.1002/iub.1556 |
| SSID | ssj0002512416 |
| Score | 2.2491064 |
| Snippet | The yellow fever virus (YFV) is a life-threatening human pathogen. Owing to the lack of available therapeutics, non-vaccinated individuals are at risk. Here,... |
| SourceID | doaj pubmedcentral proquest crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 100323 |
| SubjectTerms | complex structure human monoclonal antibody neutralizing antibody prM-binding site supersite yellow fever virus |
| Title | A neutralizing-protective supersite of human monoclonal antibodies for yellow fever virus |
| URI | https://dx.doi.org/10.1016/j.xinn.2022.100323 https://www.proquest.com/docview/2722315149 https://pubmed.ncbi.nlm.nih.gov/PMC9529537 https://doaj.org/article/bbb1a7a1063a4c57b1ab8029bcd3ac60 |
| Volume | 3 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwELYqTr1UpQ-xLUWu1ANVFbGOncQ-LqgrVAlOINGT5XEcNQgliCUt8OuZcbxoc4FLj3k78_B8E0--YexbbXSpfVlkEESJCQq4DJq6yHLtgjGBGltRonhyWh6fq18XxcVGqy-qCRvpgUfBHQCAcJXDzEU65YsKt0DPcwO-ls6XMVvHmLeRTNEcTFFbxb6nGIDKjFBx-mNmLO66azsiP81zqhKQuZxEpUjePwlOG-BzWjq5EYuWb9mbBCL5Yhz8NnsVundsO7npiu8nLunv79nvBe_CEL9mPGCQyhItA05xfDVcx4qMwPuGx1Z9HE2y91eEzTkKvIWeSgw5wlp-T2s0_3gT0PL53_ZmWH1g58ufZ0fHWeqmkHkMVBKnvaAwe0Kf0x7dzgnTCOGFrMErmcO8EYXXAmUMtLgnnQTp574EKIwLCoHJR7bV9V3YYVxLWapaN5gtgXJ1Ba52pvAiVLlvGjAzJtbStD5RjVPHiyu7rim7tKQBSxqwowZm7MfTNdcj0cazZx-Skp7OJJLsuANNxybTsS-ZzowVaxXbhDdGHIG3ap99-Ne1PVh0RlphcV3oh5XNK0RbiKEUiqCaGMpkpNMjXfsn0nobWnOV1af_8Wqf2WsacPxpUu-yrdubIXxB9HQLe9FR9uJnrUfV6hqz |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+neutralizing-protective+supersite+of+human+monoclonal+antibodies+for+yellow+fever+virus&rft.jtitle=Innovation+%28New+York%2C+NY%29&rft.au=Li%2C+Yan&rft.au=Chen%2C+Zhihai&rft.au=Wu%2C+Lili&rft.au=Dai%2C+Lianpan&rft.date=2022-11-08&rft.pub=Elsevier+Inc&rft.issn=2666-6758&rft.eissn=2666-6758&rft.volume=3&rft.issue=6&rft_id=info:doi/10.1016%2Fj.xinn.2022.100323&rft.externalDocID=S2666675822001199 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2666-6758&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2666-6758&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2666-6758&client=summon |